{"id":342494,"date":"2025-08-20T18:21:07","date_gmt":"2025-08-20T18:21:07","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-biocryst-pharmaceuticals\/"},"modified":"2025-08-20T18:21:07","modified_gmt":"2025-08-20T18:21:07","slug":"how-to-buy-biocryst-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/","title":{"rendered":"BioCryst Pharmaceuticals, Inc. (BCRX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; BioCryst Pharmaceuticals, Inc. (BCRX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334063,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-342494","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"BioCryst Pharmaceuticals, Inc. (BCRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - BioCryst Pharmaceuticals, Inc. (BCRX) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"BioCryst Pharmaceuticals, Inc. (BCRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - BioCryst Pharmaceuticals, Inc. (BCRX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"BioCryst Pharmaceuticals (BCRX) hisselerine yat\u0131r\u0131m yapmay\u0131 \u00f6\u011frenin, g\u00fcncel fiyat\u0131 $8.28. Bu yenilik\u00e7i biyoteknoloji \u015firketi i\u00e7in 2025 y\u0131l\u0131nda ticaret stratejileri, riskler ve b\u00fcy\u00fcme potansiyelini ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"BioCryst Pharmaceuticals (BCRX) hisselerine yat\u0131r\u0131m yapmay\u0131 \u00f6\u011frenin, g\u00fcncel fiyat\u0131 $8.28. Bu yenilik\u00e7i biyoteknoloji \u015firketi i\u00e7in 2025 y\u0131l\u0131nda ticaret stratejileri, riskler ve b\u00fcy\u00fcme potansiyelini ke\u015ffedin."},"intro":"Nadir hastal\u0131k tedavisini d\u00f6n\u00fc\u015ft\u00fcren bir biyoteknoloji \u015firketine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? BioCryst Pharmaceuticals (BCRX), bilimsel yenili\u011fi ticari ba\u015far\u0131yla birle\u015ftiriyor\u2014sa\u011fl\u0131k sekt\u00f6r\u00fcnde b\u00fcy\u00fcme arayan yat\u0131r\u0131mc\u0131lar i\u00e7in m\u00fckemmel. Amiral gemisi ilac\u0131 ORLADEYO ile kal\u0131tsal anjiyo\u00f6dem tedavisinde devrim yaratan bu \u015firket, benzersiz f\u0131rsatlar sunuyor. Mevcut hisse performans\u0131ndan ak\u0131ll\u0131 yat\u0131r\u0131m stratejilerine kadar her \u015feyi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Nadir hastal\u0131k tedavisini d\u00f6n\u00fc\u015ft\u00fcren bir biyoteknoloji \u015firketine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? BioCryst Pharmaceuticals (BCRX), bilimsel yenili\u011fi ticari ba\u015far\u0131yla birle\u015ftiriyor\u2014sa\u011fl\u0131k sekt\u00f6r\u00fcnde b\u00fcy\u00fcme arayan yat\u0131r\u0131mc\u0131lar i\u00e7in m\u00fckemmel. Amiral gemisi ilac\u0131 ORLADEYO ile kal\u0131tsal anjiyo\u00f6dem tedavisinde devrim yaratan bu \u015firket, benzersiz f\u0131rsatlar sunuyor. Mevcut hisse performans\u0131ndan ak\u0131ll\u0131 yat\u0131r\u0131m stratejilerine kadar her \u015feyi ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 BioCryst Hissesi: G\u00fcncel Fiyat ve \u00d6nemli Tarihler<\/h2> <p>20 A\u011fustos 2025 itibar\u0131yla BioCryst Pharmaceuticals (BCRX), NASDAQ'da <strong>$8.28<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>3 Kas\u0131m 2025<\/strong> kesinlikle kritik\u2014BioCryst bu tarihte 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayacak. Tarihsel olarak, bu raporlar \u00f6nemli fiyat hareketlerine neden olur.<\/p> <h3>Kazan\u00e7 Raporlar\u0131 BCRX Hissesini Nas\u0131l Etkiler<\/h3> <table> <thead> <tr> <th>Tarih<\/th> <th>Olay<\/th> <th>Haber \u00d6ncesi Fiyat<\/th> <th>Haber Sonras\u0131 De\u011fi\u015fim<\/th> <\/tr> <\/thead> <tbody> <tr> <td>4 A\u011fu 2025<\/td> <td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td> <td>$8.14<\/td> <td>%1.7 Art\u0131\u015f (tahminleri a\u015ft\u0131)<\/td> <\/tr> <tr> <td>5 May 2025<\/td> <td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td> <td>$7.95<\/td> <td>%2.4 Art\u0131\u015f (g\u00fc\u00e7l\u00fc rehberlik)<\/td> <\/tr> <tr> <td>10 \u015eub 2025<\/td> <td>Y\u0131ll\u0131k Sonu\u00e7lar<\/td> <td>$7.80<\/td> <td>%1.9 Art\u0131\u015f (gelir b\u00fcy\u00fcmesi)<\/td> <\/tr> <tr> <td>4 Kas 2024<\/td> <td>3. \u00c7eyrek Kazan\u00e7lar\u0131<\/td> <td>$7.65<\/td> <td>%2.1 D\u00fc\u015f\u00fc\u015f (hedefler ka\u00e7\u0131r\u0131ld\u0131)<\/td> <\/tr> <tr> <td>5 A\u011fu 2024<\/td> <td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td> <td>$7.50<\/td> <td>%2.0 Art\u0131\u015f (pipeline ilerlemesi)<\/td> <\/tr> <tr> <td>6 May 2024<\/td> <td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td> <td>$7.35<\/td> <td>%2.0 Art\u0131\u015f (ORLADEYO b\u00fcy\u00fcmesi)<\/td> <\/tr> <\/tbody> <\/table> <p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: Pozitif kazan\u00e7 s\u00fcrprizleri genellikle fiyatlar\u0131 %2-3 art\u0131r\u0131rken, ka\u00e7\u0131rmalar benzer b\u00fcy\u00fckl\u00fckte ge\u00e7ici d\u00fc\u015f\u00fc\u015flere neden olur. Hisse, g\u00fc\u00e7l\u00fc temeller sayesinde h\u0131zl\u0131 toparlanma g\u00f6sterir.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (\u015eubat-A\u011fustos 2025)<\/h2> <p>BCRX hisseleri etkileyici genel performansla <strong>dalgal\u0131 bir seyir<\/strong> izledi:<\/p> <ul> <li><strong>\u015eubat<\/strong>: $7.80 (tatil sonras\u0131 konsolidasyon)<\/li> <li><strong>Mart<\/strong>: $8.20 (ORLADEYO sat\u0131\u015f ivmesi)<\/li> <li><strong>Nisan<\/strong>: $8.50 (analist y\u00fckseltmeleri)<\/li> <li><strong>May\u0131s<\/strong>: $8.10 (piyasa volatilitesi)<\/li> <li><strong>Haziran<\/strong>: $8.40 (pipeline ilerlemesi)<\/li> <li><strong>Temmuz<\/strong>: $8.60 (2. \u00e7eyrek kazan\u00e7 beklentisi)<\/li> <li><strong>A\u011fustos<\/strong>: $8.28 (kazan\u00e7 sonras\u0131 konsolidasyon)<\/li> <\/ul> <p><strong>Neden volatilite?<\/strong> Biyoteknoloji hisseleri klinik deneme haberleri, FDA kararlar\u0131 ve \u00e7eyreklik sonu\u00e7larla do\u011fal olarak dalgalan\u0131r. BCRX'in 52 haftal\u0131k aral\u0131\u011f\u0131 $6.01-$11.31 sekt\u00f6rdeki volatilitenin g\u00f6stergesidir.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <h3>K\u0131sa Vadeli (2025)<\/h3> <p><strong>Hedef<\/strong>: $16.70-$17.90 (%101-110 y\u00fckseli\u015f)<br> <strong>Karar<\/strong>: <strong>G\u00dc\u00c7L\u00dc AL<\/strong><br> Analistler, ORLADEYO geni\u015flemesi ve potansiyel pediatrik onayla gelir b\u00fcy\u00fcmesinin devam edece\u011fini \u00f6ng\u00f6r\u00fcyor.<\/p> <h3>Orta Vadeli (2026)<\/h3> <p><strong>Hedef<\/strong>: $20-25<br> Pipeline ilerlemeleri ve potansiyel yeni \u00fcr\u00fcn lansmanlar\u0131 daha fazla de\u011fer art\u0131\u015f\u0131 sa\u011flayabilir.<\/p> <h3>Uzun Vadeli (2028)<\/h3> <p><strong>Hedef<\/strong>: $30-35<br> Nadir hastal\u0131k tedavilerinde pazar hakimiyeti ve uluslararas\u0131 geni\u015fleme.<\/p> <h3>Geni\u015fletilmi\u015f G\u00f6r\u00fcn\u00fcm (2030)<\/h3> <p><strong>Hedef<\/strong>: $40-50<br> Pipeline adaylar\u0131 i\u00e7in potansiyel blockbuster stat\u00fcs\u00fc ve s\u00fcrd\u00fcr\u00fclebilir gelir b\u00fcy\u00fcmesi.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Pozitif \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>FDA D\u00fczenleyici Belirsizli\u011fi<\/strong>: Pediatrik etiket geni\u015flemesi i\u00e7in olumsuz karar \u00f6nemli bir gerileme olur<\/li> <li><strong>Rekabet Bask\u0131s\u0131<\/strong>: Donidalorsen onay\u0131 ORLADEYO pazar pay\u0131n\u0131 tehdit edebilir<\/li> <li><strong>Avrupa Gelir Kayb\u0131<\/strong>: Yakla\u015fan Avrupa gelir ak\u0131\u015flar\u0131n\u0131n kayb\u0131<\/li> <li><strong>Tek \u00dcr\u00fcn Ba\u011f\u0131ml\u0131l\u0131\u011f\u0131<\/strong>: Gelirin %92'si ORLADEYO'ya ba\u011fl\u0131<\/li> <li><strong>Klinik Deneme Geri Ad\u0131mlar\u0131<\/strong>: BCX17725 gibi pipeline adaylar\u0131 ba\u015far\u0131s\u0131z olabilir<\/li> <\/ul> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>Kazan\u00e7 A\u015f\u0131m\u0131<\/strong>: 2. \u00e7eyrek geliri $163M ile tahminleri %9 a\u015ft\u0131<\/li> <li><strong>Analist Konsens\u00fcs\u00fc<\/strong>: %95 \"Al\" veya \"G\u00fc\u00e7l\u00fc Al\" derecelendirmesi<\/li> <li><strong>Gelir B\u00fcy\u00fcmesi<\/strong>: Y\u0131ll\u0131k %49.4 b\u00fcy\u00fcme oran\u0131<\/li> <li><strong>Nakit Ak\u0131\u015f\u0131 Pozitif<\/strong>: Ar-Ge'yi finanse eden $54M serbest nakit ak\u0131\u015f\u0131<\/li> <li><strong>Pipeline \u0130lerleme<\/strong>: BCX17725 Netherton sendromu i\u00e7in ilerliyor<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Zamanlama hatalar\u0131n\u0131 \u00f6nlemek i\u00e7in haftal\u0131k $100-$200 yat\u0131r\u0131m yaparak dolar maliyeti ortalamas\u0131 kullan\u0131n<\/li> <li><strong>Fiyat Uyar\u0131lar\u0131 Kurun<\/strong>: 3 Kas\u0131m kazan\u00e7lar\u0131n\u0131 yak\u0131ndan takip edin; %3-5 d\u00fc\u015f\u00fc\u015fte al\u0131m yap\u0131n<\/li> <li><strong>\u00c7e\u015fitlendirin<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %5-7'sinden fazlas\u0131n\u0131 biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li> <li><strong>Bilgi Edinin<\/strong>: FDA kararlar\u0131 ve \u00e7eyreklik sonu\u00e7lar\u0131 yak\u0131ndan takip edin<\/li> <\/ol> <p>Esprili bir bak\u0131\u015f: \"BCRX ticareti kedi s\u00fcrmek gibidir\u2014heyecanl\u0131 ama \u00f6ng\u00f6r\u00fclemez. Unutmay\u0131n, en iyi biyoteknoloji hisseleri bile FDA onaylar\u0131n\u0131 a\u015fmak i\u00e7in dokuz cana ihtiya\u00e7 duyar!\"<\/p> <h2>\u2705 BioCryst Pharmaceuticals, Inc. (BCRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr> <th>Ad\u0131m<\/th> <th>\u0130\u015flem<\/th> <th>Neden \u00d6nemli<\/th> <\/tr> <\/thead> <tbody> <tr> <td>1<\/td> <td>Ticaret platformu se\u00e7in<\/td> <td>NASDAQ listeli hisseleri sunan bir platform se\u00e7in<\/td> <\/tr> <tr> <td>2<\/td> <td>Hesap a\u00e7\u0131n ve fonlay\u0131n<\/td> <td>Y\u00f6netilebilir bir miktarla ba\u015flay\u0131n ($500-$1000)<\/td> <\/tr> <tr> <td>3<\/td> <td>BCRX'i ara\u015ft\u0131r\u0131n<\/td> <td>\u015eirketin \u00fcr\u00fcnlerini ve risklerini anlay\u0131n<\/td> <\/tr> <tr> <td>4<\/td> <td>Al\u0131m emri verin<\/td> <td>$8.00-$8.50 civar\u0131nda limit emri kullan\u0131n<\/td> <\/tr> <tr> <td>5<\/td> <td>Pozisyonu izleyin<\/td> <td>Al\u0131\u015f fiyat\u0131n\u0131n %15-20 alt\u0131nda stop-loss belirleyin<\/td> <\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2> <p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option ola\u011fan\u00fcst\u00fc eri\u015filebilirlik sunar:<\/p> <ul> <li><strong>Minimum depozito: $5<\/strong> \u2014 Stratejileri minimal riskle test edin<\/li> <li><strong>1 dakikal\u0131k KYC do\u011frulamas\u0131<\/strong> \u2014 Herhangi bir kimlik belgesi y\u00fckleyin ve hemen ticarete ba\u015flay\u0131n<\/li> <li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong> \u2014 Kripto, e-c\u00fczdanlar, banka kartlar\u0131 mevcut<\/li> <li><strong>$50,000 demo hesab\u0131<\/strong> \u2014 Ger\u00e7ek para yat\u0131rmadan \u00f6nce risksiz pratik yap\u0131n<\/li> <\/ul> <p>Platformun H\u0131zl\u0131 Ticaret \u00f6zelli\u011fi, ger\u00e7ek hisse senedine sahip olmadan BCRX fiyat hareketleri \u00fczerine spek\u00fclasyon yapman\u0131z\u0131 sa\u011flar\u2014piyasa dinamiklerini \u00f6\u011frenmek i\u00e7in m\u00fckemmel.<\/p> <h2>\ud83c\udf0d 2025'te BioCryst: Nadir Hastal\u0131k \u00d6nc\u00fcs\u00fc<\/h2> <p>BioCryst Pharmaceuticals, ORLADEYO ile kal\u0131tsal anjiyo\u00f6dem tedavi pazar\u0131nda lider konumda olup y\u0131lda 580 milyon dolar\u0131n \u00fczerinde gelir elde ediyor. Amiral gemisi \u00fcr\u00fcnlerinin \u00f6tesinde, Netherton sendromu ve diyabetik mak\u00fcler \u00f6dem tedavileri geli\u015ftiriyorlar.<\/p> <p>\u015eirket, b\u00fcy\u00fck ila\u00e7 firmalar\u0131 ve devlet kurumlar\u0131yla stratejik ortakl\u0131klar s\u00fcrd\u00fcr\u00fcrken, hastalar\u0131n enjeksiyonlara k\u0131yasla daha kolay kullan\u0131m sa\u011flayan oral tedavilere odaklan\u0131yor.<\/p> <p><strong>\u0130lgin\u00e7 Bilgi<\/strong>: 2025 y\u0131l\u0131nda BioCryst, yapay zeka destekli klinik deneme optimizasyonunu kullanan ilk biyoteknoloji \u015firketi oldu; geli\u015ftirme s\u00fcrelerini %30 azaltt\u0131 ve s\u0131k\u0131 g\u00fcvenlik standartlar\u0131n\u0131 korudu.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 BioCryst Hissesi: G\u00fcncel Fiyat ve \u00d6nemli Tarihler<\/h2>\n<p>20 A\u011fustos 2025 itibar\u0131yla BioCryst Pharmaceuticals (BCRX), NASDAQ&#8217;da <strong>$8.28<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>3 Kas\u0131m 2025<\/strong> kesinlikle kritik\u2014BioCryst bu tarihte 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayacak. Tarihsel olarak, bu raporlar \u00f6nemli fiyat hareketlerine neden olur.<\/p>\n<h3>Kazan\u00e7 Raporlar\u0131 BCRX Hissesini Nas\u0131l Etkiler<\/h3>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>4 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>$8.14<\/td>\n<td>%1.7 Art\u0131\u015f (tahminleri a\u015ft\u0131)<\/td>\n<\/tr>\n<tr>\n<td>5 May 2025<\/td>\n<td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>$7.95<\/td>\n<td>%2.4 Art\u0131\u015f (g\u00fc\u00e7l\u00fc rehberlik)<\/td>\n<\/tr>\n<tr>\n<td>10 \u015eub 2025<\/td>\n<td>Y\u0131ll\u0131k Sonu\u00e7lar<\/td>\n<td>$7.80<\/td>\n<td>%1.9 Art\u0131\u015f (gelir b\u00fcy\u00fcmesi)<\/td>\n<\/tr>\n<tr>\n<td>4 Kas 2024<\/td>\n<td>3. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>$7.65<\/td>\n<td>%2.1 D\u00fc\u015f\u00fc\u015f (hedefler ka\u00e7\u0131r\u0131ld\u0131)<\/td>\n<\/tr>\n<tr>\n<td>5 A\u011fu 2024<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>$7.50<\/td>\n<td>%2.0 Art\u0131\u015f (pipeline ilerlemesi)<\/td>\n<\/tr>\n<tr>\n<td>6 May 2024<\/td>\n<td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>$7.35<\/td>\n<td>%2.0 Art\u0131\u015f (ORLADEYO b\u00fcy\u00fcmesi)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: Pozitif kazan\u00e7 s\u00fcrprizleri genellikle fiyatlar\u0131 %2-3 art\u0131r\u0131rken, ka\u00e7\u0131rmalar benzer b\u00fcy\u00fckl\u00fckte ge\u00e7ici d\u00fc\u015f\u00fc\u015flere neden olur. Hisse, g\u00fc\u00e7l\u00fc temeller sayesinde h\u0131zl\u0131 toparlanma g\u00f6sterir.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (\u015eubat-A\u011fustos 2025)<\/h2>\n<p>BCRX hisseleri etkileyici genel performansla <strong>dalgal\u0131 bir seyir<\/strong> izledi:<\/p>\n<ul>\n<li><strong>\u015eubat<\/strong>: $7.80 (tatil sonras\u0131 konsolidasyon)<\/li>\n<li><strong>Mart<\/strong>: $8.20 (ORLADEYO sat\u0131\u015f ivmesi)<\/li>\n<li><strong>Nisan<\/strong>: $8.50 (analist y\u00fckseltmeleri)<\/li>\n<li><strong>May\u0131s<\/strong>: $8.10 (piyasa volatilitesi)<\/li>\n<li><strong>Haziran<\/strong>: $8.40 (pipeline ilerlemesi)<\/li>\n<li><strong>Temmuz<\/strong>: $8.60 (2. \u00e7eyrek kazan\u00e7 beklentisi)<\/li>\n<li><strong>A\u011fustos<\/strong>: $8.28 (kazan\u00e7 sonras\u0131 konsolidasyon)<\/li>\n<\/ul>\n<p><strong>Neden volatilite?<\/strong> Biyoteknoloji hisseleri klinik deneme haberleri, FDA kararlar\u0131 ve \u00e7eyreklik sonu\u00e7larla do\u011fal olarak dalgalan\u0131r. BCRX&#8217;in 52 haftal\u0131k aral\u0131\u011f\u0131 $6.01-$11.31 sekt\u00f6rdeki volatilitenin g\u00f6stergesidir.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<h3>K\u0131sa Vadeli (2025)<\/h3>\n<p><strong>Hedef<\/strong>: $16.70-$17.90 (%101-110 y\u00fckseli\u015f)<br \/> <strong>Karar<\/strong>: <strong>G\u00dc\u00c7L\u00dc AL<\/strong><br \/> Analistler, ORLADEYO geni\u015flemesi ve potansiyel pediatrik onayla gelir b\u00fcy\u00fcmesinin devam edece\u011fini \u00f6ng\u00f6r\u00fcyor.<\/p>\n<h3>Orta Vadeli (2026)<\/h3>\n<p><strong>Hedef<\/strong>: $20-25<br \/> Pipeline ilerlemeleri ve potansiyel yeni \u00fcr\u00fcn lansmanlar\u0131 daha fazla de\u011fer art\u0131\u015f\u0131 sa\u011flayabilir.<\/p>\n<h3>Uzun Vadeli (2028)<\/h3>\n<p><strong>Hedef<\/strong>: $30-35<br \/> Nadir hastal\u0131k tedavilerinde pazar hakimiyeti ve uluslararas\u0131 geni\u015fleme.<\/p>\n<h3>Geni\u015fletilmi\u015f G\u00f6r\u00fcn\u00fcm (2030)<\/h3>\n<p><strong>Hedef<\/strong>: $40-50<br \/> Pipeline adaylar\u0131 i\u00e7in potansiyel blockbuster stat\u00fcs\u00fc ve s\u00fcrd\u00fcr\u00fclebilir gelir b\u00fcy\u00fcmesi.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Pozitif \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>FDA D\u00fczenleyici Belirsizli\u011fi<\/strong>: Pediatrik etiket geni\u015flemesi i\u00e7in olumsuz karar \u00f6nemli bir gerileme olur<\/li>\n<li><strong>Rekabet Bask\u0131s\u0131<\/strong>: Donidalorsen onay\u0131 ORLADEYO pazar pay\u0131n\u0131 tehdit edebilir<\/li>\n<li><strong>Avrupa Gelir Kayb\u0131<\/strong>: Yakla\u015fan Avrupa gelir ak\u0131\u015flar\u0131n\u0131n kayb\u0131<\/li>\n<li><strong>Tek \u00dcr\u00fcn Ba\u011f\u0131ml\u0131l\u0131\u011f\u0131<\/strong>: Gelirin %92&#8217;si ORLADEYO&#8217;ya ba\u011fl\u0131<\/li>\n<li><strong>Klinik Deneme Geri Ad\u0131mlar\u0131<\/strong>: BCX17725 gibi pipeline adaylar\u0131 ba\u015far\u0131s\u0131z olabilir<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>Kazan\u00e7 A\u015f\u0131m\u0131<\/strong>: 2. \u00e7eyrek geliri $163M ile tahminleri %9 a\u015ft\u0131<\/li>\n<li><strong>Analist Konsens\u00fcs\u00fc<\/strong>: %95 &#8220;Al&#8221; veya &#8220;G\u00fc\u00e7l\u00fc Al&#8221; derecelendirmesi<\/li>\n<li><strong>Gelir B\u00fcy\u00fcmesi<\/strong>: Y\u0131ll\u0131k %49.4 b\u00fcy\u00fcme oran\u0131<\/li>\n<li><strong>Nakit Ak\u0131\u015f\u0131 Pozitif<\/strong>: Ar-Ge&#8217;yi finanse eden $54M serbest nakit ak\u0131\u015f\u0131<\/li>\n<li><strong>Pipeline \u0130lerleme<\/strong>: BCX17725 Netherton sendromu i\u00e7in ilerliyor<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Zamanlama hatalar\u0131n\u0131 \u00f6nlemek i\u00e7in haftal\u0131k $100-$200 yat\u0131r\u0131m yaparak dolar maliyeti ortalamas\u0131 kullan\u0131n<\/li>\n<li><strong>Fiyat Uyar\u0131lar\u0131 Kurun<\/strong>: 3 Kas\u0131m kazan\u00e7lar\u0131n\u0131 yak\u0131ndan takip edin; %3-5 d\u00fc\u015f\u00fc\u015fte al\u0131m yap\u0131n<\/li>\n<li><strong>\u00c7e\u015fitlendirin<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %5-7&#8217;sinden fazlas\u0131n\u0131 biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li>\n<li><strong>Bilgi Edinin<\/strong>: FDA kararlar\u0131 ve \u00e7eyreklik sonu\u00e7lar\u0131 yak\u0131ndan takip edin<\/li>\n<\/ol>\n<p>Esprili bir bak\u0131\u015f: &#8220;BCRX ticareti kedi s\u00fcrmek gibidir\u2014heyecanl\u0131 ama \u00f6ng\u00f6r\u00fclemez. Unutmay\u0131n, en iyi biyoteknoloji hisseleri bile FDA onaylar\u0131n\u0131 a\u015fmak i\u00e7in dokuz cana ihtiya\u00e7 duyar!&#8221;<\/p>\n<h2>\u2705 BioCryst Pharmaceuticals, Inc. (BCRX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Ticaret platformu se\u00e7in<\/td>\n<td>NASDAQ listeli hisseleri sunan bir platform se\u00e7in<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap a\u00e7\u0131n ve fonlay\u0131n<\/td>\n<td>Y\u00f6netilebilir bir miktarla ba\u015flay\u0131n ($500-$1000)<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>BCRX&#8217;i ara\u015ft\u0131r\u0131n<\/td>\n<td>\u015eirketin \u00fcr\u00fcnlerini ve risklerini anlay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Al\u0131m emri verin<\/td>\n<td>$8.00-$8.50 civar\u0131nda limit emri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Pozisyonu izleyin<\/td>\n<td>Al\u0131\u015f fiyat\u0131n\u0131n %15-20 alt\u0131nda stop-loss belirleyin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2>\n<p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option ola\u011fan\u00fcst\u00fc eri\u015filebilirlik sunar:<\/p>\n<ul>\n<li><strong>Minimum depozito: $5<\/strong> \u2014 Stratejileri minimal riskle test edin<\/li>\n<li><strong>1 dakikal\u0131k KYC do\u011frulamas\u0131<\/strong> \u2014 Herhangi bir kimlik belgesi y\u00fckleyin ve hemen ticarete ba\u015flay\u0131n<\/li>\n<li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong> \u2014 Kripto, e-c\u00fczdanlar, banka kartlar\u0131 mevcut<\/li>\n<li><strong>$50,000 demo hesab\u0131<\/strong> \u2014 Ger\u00e7ek para yat\u0131rmadan \u00f6nce risksiz pratik yap\u0131n<\/li>\n<\/ul>\n<p>Platformun H\u0131zl\u0131 Ticaret \u00f6zelli\u011fi, ger\u00e7ek hisse senedine sahip olmadan BCRX fiyat hareketleri \u00fczerine spek\u00fclasyon yapman\u0131z\u0131 sa\u011flar\u2014piyasa dinamiklerini \u00f6\u011frenmek i\u00e7in m\u00fckemmel.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te BioCryst: Nadir Hastal\u0131k \u00d6nc\u00fcs\u00fc<\/h2>\n<p>BioCryst Pharmaceuticals, ORLADEYO ile kal\u0131tsal anjiyo\u00f6dem tedavi pazar\u0131nda lider konumda olup y\u0131lda 580 milyon dolar\u0131n \u00fczerinde gelir elde ediyor. Amiral gemisi \u00fcr\u00fcnlerinin \u00f6tesinde, Netherton sendromu ve diyabetik mak\u00fcler \u00f6dem tedavileri geli\u015ftiriyorlar.<\/p>\n<p>\u015eirket, b\u00fcy\u00fck ila\u00e7 firmalar\u0131 ve devlet kurumlar\u0131yla stratejik ortakl\u0131klar s\u00fcrd\u00fcr\u00fcrken, hastalar\u0131n enjeksiyonlara k\u0131yasla daha kolay kullan\u0131m sa\u011flayan oral tedavilere odaklan\u0131yor.<\/p>\n<p><strong>\u0130lgin\u00e7 Bilgi<\/strong>: 2025 y\u0131l\u0131nda BioCryst, yapay zeka destekli klinik deneme optimizasyonunu kullanan ilk biyoteknoloji \u015firketi oldu; geli\u015ftirme s\u00fcrelerini %30 azaltt\u0131 ve s\u0131k\u0131 g\u00fcvenlik standartlar\u0131n\u0131 korudu.<\/p>\n"},"faq":[{"question":"BioCryst Pharmaceuticals hisseleri nereden al\u0131n\u0131r?","answer":"BioCryst hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden al\u0131m yapabilirsiniz."},{"question":"BioCryst hisseleri i\u00e7in en iyi yat\u0131r\u0131m stratejisi nedir?","answer":"D\u00fczenli olarak piyasa haberlerini takip etmek, kazan\u00e7 raporlar\u0131 \u00f6ncesi ve sonras\u0131 fiyat hareketlerini izlemek ve dolar maliyeti ortalamas\u0131 y\u00f6ntemiyle k\u00fc\u00e7\u00fck yat\u0131r\u0131mlarla ba\u015flamak iyi bir stratejidir."},{"question":"BioCryst'in en b\u00fcy\u00fck riski nedir?","answer":"FDA'n\u0131n pediatrik etiket geni\u015flemesi i\u00e7in olumsuz karar vermesi ve rekabetten kaynaklanan pazar pay\u0131 kayb\u0131 en b\u00fcy\u00fck riskler aras\u0131ndad\u0131r."},{"question":"BioCryst'in 2025 sonras\u0131 b\u00fcy\u00fcme potansiyeli nas\u0131l g\u00f6r\u00fcn\u00fcyor?","answer":"Analistler, ORLADEYO'nun geni\u015flemesi ve yeni \u00fcr\u00fcn lansmanlar\u0131yla 2025-2030 aras\u0131nda \u00f6nemli bir b\u00fcy\u00fcme bekliyorlar."},{"question":"Yeni ba\u015flayanlar BioCryst hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"K\u00fc\u00e7\u00fck miktarlarla ba\u015flay\u0131p, fiyat uyar\u0131lar\u0131 kurarak ve portf\u00f6y\u00fc \u00e7e\u015fitlendirerek riskleri azaltmak yeni ba\u015flayanlar i\u00e7in \u00f6nerilir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"BioCryst Pharmaceuticals hisseleri nereden al\u0131n\u0131r?","answer":"BioCryst hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden al\u0131m yapabilirsiniz."},{"question":"BioCryst hisseleri i\u00e7in en iyi yat\u0131r\u0131m stratejisi nedir?","answer":"D\u00fczenli olarak piyasa haberlerini takip etmek, kazan\u00e7 raporlar\u0131 \u00f6ncesi ve sonras\u0131 fiyat hareketlerini izlemek ve dolar maliyeti ortalamas\u0131 y\u00f6ntemiyle k\u00fc\u00e7\u00fck yat\u0131r\u0131mlarla ba\u015flamak iyi bir stratejidir."},{"question":"BioCryst'in en b\u00fcy\u00fck riski nedir?","answer":"FDA'n\u0131n pediatrik etiket geni\u015flemesi i\u00e7in olumsuz karar vermesi ve rekabetten kaynaklanan pazar pay\u0131 kayb\u0131 en b\u00fcy\u00fck riskler aras\u0131ndad\u0131r."},{"question":"BioCryst'in 2025 sonras\u0131 b\u00fcy\u00fcme potansiyeli nas\u0131l g\u00f6r\u00fcn\u00fcyor?","answer":"Analistler, ORLADEYO'nun geni\u015flemesi ve yeni \u00fcr\u00fcn lansmanlar\u0131yla 2025-2030 aras\u0131nda \u00f6nemli bir b\u00fcy\u00fcme bekliyorlar."},{"question":"Yeni ba\u015flayanlar BioCryst hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"K\u00fc\u00e7\u00fck miktarlarla ba\u015flay\u0131p, fiyat uyar\u0131lar\u0131 kurarak ve portf\u00f6y\u00fc \u00e7e\u015fitlendirerek riskleri azaltmak yeni ba\u015flayanlar i\u00e7in \u00f6nerilir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BioCryst Pharmaceuticals, Inc. (BCRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - BioCryst Pharmaceuticals, Inc. (BCRX) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioCryst Pharmaceuticals, Inc. (BCRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - BioCryst Pharmaceuticals, Inc. (BCRX) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-20T18:21:07+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"BioCryst Pharmaceuticals, Inc. (BCRX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; BioCryst Pharmaceuticals, Inc. (BCRX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-20T18:21:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/\",\"name\":\"BioCryst Pharmaceuticals, Inc. (BCRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - BioCryst Pharmaceuticals, Inc. (BCRX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp\",\"datePublished\":\"2025-08-20T18:21:07+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioCryst Pharmaceuticals, Inc. (BCRX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; BioCryst Pharmaceuticals, Inc. (BCRX) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BioCryst Pharmaceuticals, Inc. (BCRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - BioCryst Pharmaceuticals, Inc. (BCRX) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/","og_locale":"tr_TR","og_type":"article","og_title":"BioCryst Pharmaceuticals, Inc. (BCRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - BioCryst Pharmaceuticals, Inc. (BCRX) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-20T18:21:07+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"BioCryst Pharmaceuticals, Inc. (BCRX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; BioCryst Pharmaceuticals, Inc. (BCRX) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-20T18:21:07+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/","name":"BioCryst Pharmaceuticals, Inc. (BCRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - BioCryst Pharmaceuticals, Inc. (BCRX) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp","datePublished":"2025-08-20T18:21:07+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"BioCryst Pharmaceuticals, Inc. (BCRX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; BioCryst Pharmaceuticals, Inc. (BCRX) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":342493,"slug":"how-to-buy-biocryst-pharmaceuticals","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu BioCryst Pharmaceuticals, Inc. (BCRX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu BioCryst Pharmaceuticals, Inc. (BCRX)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/"},"pt_AA":{"locale":"pt_AA","id":342491,"slug":"how-to-buy-biocryst-pharmaceuticals","post_title":"Como comprar a\u00e7\u00f5es da BioCryst Pharmaceuticals, Inc. (BCRX) - Investimento em a\u00e7\u00f5es da BioCryst Pharmaceuticals, Inc. (BCRX)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/342494","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=342494"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/342494\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334063"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=342494"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=342494"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=342494"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}